Literature DB >> 1323621

Acquisition of Clostridium difficile by hospitalized patients: evidence for colonized new admissions as a source of infection.

C R Clabots1, S Johnson, M M Olson, L R Peterson, D N Gerding.   

Abstract

The frequency of introduction and spread of specific Clostridium difficile strains among hospitalized patients were assessed by serial cultures of patients admitted to a medical-surgical ward with endemic C. difficile-associated diarrhea. Stool cultures were obtained from 634 (94%) of 678 consecutive admissions to the ward (ward admissions), and all C. difficile isolates were typed by restriction endonuclease analysis. Sixty-five ward admissions introduced C. difficile to the ward, and 54 initially culture-negative admissions acquired C. difficile on the ward. Ward admissions hospitalized within the prior 30 days in the medical center were more likely to be culture-positive for C. difficile at admission to the study ward than those not previously hospitalized at the institution (16% vs. 7%, P less than .001). Nosocomial acquisition of a C. difficile strain was preceded by a documented introduction of that strain to the ward by another asymptomatic ward admission in 16 (84%) of 19 instances, suggesting that C. difficile-colonized new admissions are a major source of nosocomial C. difficile infections.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1323621     DOI: 10.1093/infdis/166.3.561

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  102 in total

1.  Prevention of healthcare‐associated Clostridium difficile infection: what works?

Authors:  Erik R Dubberke
Journal:  Infect Control Hosp Epidemiol       Date:  2010-11       Impact factor: 3.254

2.  Epidemiology of recurrences or reinfections of Clostridium difficile-associated diarrhea.

Authors:  F Barbut; A Richard; K Hamadi; V Chomette; B Burghoffer; J C Petit
Journal:  J Clin Microbiol       Date:  2000-06       Impact factor: 5.948

3.  Successful use of nitazoxanide in the treatment of recurrent Clostridium difficile infection.

Authors:  Fnu Rafiullah; Sunil Kanwal; Usman M Majeed; Mark A Korsten; Faisal H Cheema; Munish Luthra; Muhammad Rizwan Sohail
Journal:  BMJ Case Rep       Date:  2011-11-21

Review 4.  Recognition and prevention of hospital-associated enteric infections in the intensive care unit.

Authors:  Linda D Bobo; Erik R Dubberke
Journal:  Crit Care Med       Date:  2010-08       Impact factor: 7.598

5.  Hospital-associated Clostridium difficile infection: is it necessary to track community-onset disease?

Authors:  Erik R Dubberke; Kathleen M McMullen; Jennie L Mayfield; Kimberly A Reske; Peter Georgantopoulos; David K Warren; Victoria J Fraser
Journal:  Infect Control Hosp Epidemiol       Date:  2009-04       Impact factor: 3.254

6.  Clostridium difficile associated diarrhoea in hospitalised patients: onset in the community and hospital and role of flexible sigmoidoscopy.

Authors:  S S Johal; J Hammond; K Solomon; P D James; Y R Mahida
Journal:  Gut       Date:  2004-05       Impact factor: 23.059

Review 7.  Understanding Clostridium difficile Colonization.

Authors:  Monique J T Crobach; Jonathan J Vernon; Vivian G Loo; Ling Yuan Kong; Séverine Péchiné; Mark H Wilcox; Ed J Kuijper
Journal:  Clin Microbiol Rev       Date:  2018-03-14       Impact factor: 26.132

8.  Risk factors for Clostridium difficile-associated diarrhea on an adult hematology-oncology ward.

Authors:  A H Gifford; K B Kirkland
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2006-12       Impact factor: 3.267

Review 9.  Clostridium difficile infection: epidemiology, diagnosis and understanding transmission.

Authors:  Jessica S H Martin; Tanya M Monaghan; Mark H Wilcox
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2016-03-09       Impact factor: 46.802

Review 10.  A review of the economics of treating Clostridium difficile infection.

Authors:  Kari A Mergenhagen; Amy L Wojciechowski; Joseph A Paladino
Journal:  Pharmacoeconomics       Date:  2014-07       Impact factor: 4.981

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.